NewAmsterdam Pharma N.V. (NAMS) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 483.4% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with +27.5% for SLS. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.51 billion vs $2.36 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | SLS |
|---|---|---|
| Share price | $21.44 | $11.69 |
| Market cap | $2.51B | $2.36B |
| 1-day change | +0.85% | +3.82% |
| YTD return | -39.40% | +198.67% |
| 1-year return | -35.30% | +483.42% |
| 5-year return | +117.16% | +27.52% |
| EPS (TTM) | $-2.16 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | — |
| Revenue growth (YoY) | -50.61% | — |
| Net income (latest FY) | $-203.82M | $-26.86M |
| Operating margin | -1002.90% | — |
| Net margin | -905.74% | — |
| 52-week high | $42.21 | $15.88 |
| 52-week low | $20.91 | $1.39 |
| Distance from 52-week high | -49.20% | -26.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +131.58% | +178.02% |
| Average volume | 1.36M | 6.52M |
| Shares outstanding | 116.90M | 201.95M |
| Employees | 100 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed NAMS by 518.7 percentage points over the past year.
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
NAMS vs SLS FAQ
Which is bigger, NewAmsterdam Pharma N.V. or SELLAS Life Sciences Group?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.51B compared with $2.36B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, NAMS or SLS?
SLS returned +483.42% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.